IMS
Vārānasi, India
IMS
Vārānasi, India

Time filter

Source Type

Research and Markets has announced the addition of the "Spectroscopy Equipment and Accessories - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Spectroscopy Equipment and Accessories in US$ Thousand by the following Product Segments: The report profiles 117 companies including many key and niche players such as: 1. OUTLOOK A Prelude Overview Current and Future Analysis Sustained Growth for Aftermarket Products and Services 2. MARKET OVERVIEW Government Funding and Research Activities Propel Molecular Spectroscopy Market Growing Preference for Handheld Instruments Infrared Spectroscopy - A Peek into Technology and Application Trends Raman Spectroscopy - A Review of Advanced Technologies and Applications Tip-enhanced Raman Spectroscopy (TERS) Surface-enhanced Raman Spectroscopy (SERS) Spatially Offset Raman Spectroscopy (SORS) Magnetic Photoacoustoic Raman (MPR) Raman Spectroscopy Emerges as Attractive Analytical Tool for Pharmaceutical Industry Fluorescence Spectroscopy - A Gold Standard Technology Atomic Spectroscopy - An Overview Mass Spectrometry: Technological Developments and Expanding End-Use Applications to Bolster Growth Review of Select MS Technologies The Way Ahead for FT-MS and Magnetic Sector MS Technologies Portability: A Major Driving Force for MS Systems Market Nanotube Coating to Enable Miniaturization in Mass Spectrometers High Prices of MS Systems Hold Down Sales Growth Purpose-Built Mass Spectrometers to Transform Personalized Medicine Leading End Users of Mass Spectrometry Devices A Peek into Regulatory and Competitive Landscape in MS Ion-Trap Mass Spectrometry Technology Losses Sheen Reduced Government Spending on Laboratory Testing Lack of Suitable Software and Diversity of MS Systems - A Major Challenge Smaller Clinical Laboratories Continue to Shy Away from Mass Spectrometers 3. MARKET TRENDS & ISSUES Rise in Drug Development Outsourcing to Fuel Global Spectroscopy Market Growing Significance of Miniaturization in Spectroscopy Shift of Analytical Instruments Industry to Mass Customization Improved Mobility Broadens the Role of Spectroscopy Improved Analyzer Reliability and Performance Hyphenated Technologies Exhibit Growth Spectroscopy Makes Inroads into Novel Applications Applications Extend to Defense and Civilian Areas Atomic and Molecular Spectrometers Benefit from Technological Improvements Demand for Used Spectroscopy Instruments to Grow Robustly in Future 4. COMPETITIVE LANDSCAPE Competition in the Spectrometry Market: An Insight Molecular Spectroscopy: A Highly Fragmented Market List of Leading Players in the Global Molecular Spectroscopy Market by Product Type Atomic Spectroscopy Market List of Leading Players in the Global Atomic Spectroscopy Market Mass Spectrometry Market List of Leading Players in the Global Mass Spectrometry Market 5. PRODUCT OVERVIEW Spectroscopy Spectrophotometer Fluorometer Different Types of Spectrophotometry Analysis Infrared Spectrophotometry Near-Infrared Spectrophotometry Visible Spectrophotometry Ion Mobility Spectrometry Color Spectrophotometry Near-Ultraviolet Spectrophotometry Spectrometry Spectrometers: A Broad Spectrum of Devices A. Molecular Spectroscopy - The Study of Absorption of Light by Molecules Ultraviolet/Visible (UV/VIS) Spectroscopy Raman Spectroscopy Nuclear Magnetic Resonance (NMR) Spectrometers Near Infrared (NIR) Spectroscopy Applications of Near-IR Techniques Process Analysis Applications of the NIR Spectroscopy Infrared Spectroscopy Fourier-Transform Infrared (FTIR) Spectroscopy B. Atomic Spectroscopy Arc/Spark Spectrometry ICP and ICP-MS Atomic Absorption Spectroscopy Atomic Absorption Analysis Instrumentation Atomizers Double Beam Systems Applications Trends and Future Developments X-Ray Fluorescence Spectrometers (XRF) C. Mass Spectrometry (MS) Mass Spectrometer Types of Mass Spectrometers and their Applications Liquid Chromatography-Mass Spectrometry (LC-MS) Gas Chromatography-Mass Spectrometry (GC-MS) MALDI-TOF Fluorescence Spectroscopy - An Overview Biomedical Applications of Fluorescence Spectroscopy Fluorescence Quenching Fluorescence Polarization Resonance Energy Transfer Filter Fluorimeters Spectrofluorimeters Monochromators Fluorescence-Lifetime Measurements 6. PRODUCT INNOVATIONS/INTRODUCTIONS Shimadzu Launches LCMS-8045 Mass Spectrometer in Europe JUKI Group Commercializes AY555 Spectrophotometer Avantes Launches AvaSpec-Hero Sensline Spectrometer Agilent Launches New 4210 Microwave Plasma-Atomic Emission Spectrometer Princeton Launches FERGIE Spectroscopy System Konica Minolta Introduces Automobile Specific Spectrophotometers, CM-25cG and CM-M6 Shimadzu Launches New GC-MS/MS System, GCMS-TQ8050 Datacolor Introduces Datacolor 20D for Paint Retailers StellarNet Launches Portable Research Grade Raman Spectroscopy System Jenway® Launches New Visible Scanning Spectrophotometer, 7200 IRsweep to Launch IRspectrometer Shimadzu Introduces Atomic Absorption Spectrophotometer, AA-6880F Bruker Launches timsTOF System Thermo Fisher Launches New Spectrometry Devices Techkon Launches Continuous Scanning Spectrophotometer, SpectroEdge ES7500 Sciex Introduces SCIEX QTRAP® 6500+ LC-MS/MS System StellarNet Launches RED-Wave-NIRX-SR Spectrometer Thermo Scientific Launches NanoDrop One Spectrophotometers Thermo Scientific Launches GENESYS 30 Visible-Range Spectrophotometer Thermo Scientific Launches New DXR2 Line of Raman Microscopes Bruker Launches Total Reflection X-Ray Fluorescence Spectrometer, S4 TStar Agilent Launches 5110 ICP-OES Magritek Introduces 60 MHz Benchtop NMR Spectrometers, Spinsolve 60 Thermo Scientific Launches New FT-NIR Spectrometer, Nicolet iS5N Rigaku Launches New Benchtop Variable Spot EDXRF Spectrometer, Rigaku NEX DE Advion Introduces TIDES EXPRESS Merck Introduces Spectroquant® Prove Spectrophotometers Shimadzu Introduces Inductively Coupled Plasma Mass Spectrometer, ICPMS-2030 AQULABO Group Introduces Uviline 9300 and Uviline 9600 Rigaku Launches Rigaku ZSX Primus IV StellarNet BLUE-Wave Compact Spectrometers Line SPECTRO Introduces New Line of SPECTRO XEPOS Spectrometers Thermo Fisher Introduces Thermo Scientific 253 Ultra HR-IRMS StellarNet Launches BLACK-Comet-HR Specac Introduces Pearl Liquid Analysis Accessory Agilent Introduces Agilent 5977B HES GC/MSD System in China Datacolor Introduces New Line of Color Measurement Spectrophotometers Bruker Introduces HH-LIBS Device, EOS 500 Bruker Launches 10 kHz rapifleX MALDI-TOF/TOF Mass Spectrometer Konica Minolta Introduces Auto-Scanning Spectrophotometer, FD-9 Rigaku Introduces Rigaku NANOHUNTER II TXRF Spectrometer SPECTRO Introduces New SPECTROLAB Arc/Spark Optical Emission Spectrometers SPECTRO Introduces SPECTROSCOUT X-ray Fluorescence Spectrometer Bruker Introduces S2 PUMA Shimadzu Introduces Shimadzu LCMS-8060 Triple Quadrupole Mass Spectrometer Thermo Scientific Launches Orbitrap Fusion Lumos Tribrid Mass Spectrometer Agilent Introduces Agilent 6470 Triple Quadrupole LC/MS Waters Introduces Vion IMS QTof Mass Spectrometer DeNovix Introduces DS-11 FX+ Spectrophotometer / Fluorometer Agilent Launches Agilent 6545 Q-TOF Mass Spectrometry System Implen Introduces Fourth Generation NanoPhotometer® Spectrophotometers Shimadzu Corporation Compact Monochromator System Package, SPG-120-REV JEOL Develops JPS-9030, X-ray Photoelectron Spectrometer Datacolor Introduces CHECK 3 Portable Spectrophotometer SPECTRO Launches SPECTRO xSort Handheld EDXRF Spectrometers Bruker Handheld Raman Spectrometer, BRAVO Shimadzu Launches RF-6000 Spectrofluorophotometer X-Rite Introduces X-Rite Ci7800 and X-Rite Ci7600 SPECTRO Introduces SPECTRO xSORT Line of Handheld EDXRF Spectrometers Analytik Jena Introduces New ICP-MS Products, PlasmaQuant® MS and PlasmaQuant® MS Elite Ocean Optics Introduces New Miniature Spectrometer, Flame Shimadzu Launches UV1280 UVVIS Spectrophotometer in the US SPECTRO Introduces SPECTRO ARCOS High-Resolution Spectrometer JEOL Launches JMS-T200GC High-end GC-TOFMS Thermo Scientific Launches Orbitrap Based Q Exactive Focus LC MS/MS Mass Spectrometer 7. RECENT INDUSTRY ACTIVITY Bruker Acquires Active Spectrum Inc. Wasatch Photonics Acquires Process Raman Spectroscopy Technology from Mustard Tree Instruments Shimadzu Institutes Shimadzu China Mass Spectrometry Center INSION Enters into Distribution Agreement with Digilab - The United States (75) - Canada (2) - Japan (11) - Europe (40) - France (3) - Germany (11) - The United Kingdom (18) - Italy (1) - Spain (1) - Rest of Europe (6) - Asia-Pacific (Excluding Japan) (9) - Middle East (1) For more information about this report visit http://www.researchandmarkets.com/research/gxbsmg/spectroscopy


News Article | February 15, 2017
Site: www.marketwired.com

CounterPath continues to drive device testing with Bria X to ensure maximum support across a variety of USB and wireless headsets VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 8, 2017) - CounterPath Corporation (NASDAQ:CPAH)(TSX:PATH), a global provider of award-winning, over-the-top (OTT) Unified Communications (UC) solutions for enterprises and carriers, today announced the certified interoperability of Jabra USB and Bluetooth headset devices with CounterPath's latest offering, Bria X. This is the second in a series of interoperability testing phases with Bria X and various headset vendors to provide an optimized user experience - from software to headset - across any device, any network and any platform. "This is another win for CounterPath and Bria X on the interoperability certification and user experience front," said Todd Carothers, Executive Vice President of Sales and Marketing, CounterPath. Users of Jabra headsets will be prompted to install Jabra Direct software on their desktop, if they haven't already, from the Notification Tab within Bria X. Once installed, users will have access to a multitude of functions such as synchronization between Bria X and their headset for answer / hang up call, mute, and hold call. In addition, users are able to switch audio between devices, for example from their Jabra headset to the built-in speaker on their device, and also set functionality for the ringing of incoming calls on the headset or speaker as well. "Demand for headsets, especially wireless ones, in the workplace is increasing due to the valuable functions they provide. They offer employees the freedom and mobility that modern work environments and business situations require," continued Carothers. "With Bria X providing users with a plethora of UC tools, having tight headset integration and mobile capabilities is important to ensure the solution is a natural extension to users. The Jabra certification is yet another example of our commitment to providing the best user experience across any device, network and platform." For a full list of supported devices using Bria X please visit: http://www.counterpath.com/technology-partner-program/. CounterPath Unified Communications solutions are changing the face of telecommunications. An industry and user favorite, Bria softphones for desktop, tablet and mobile devices, together with Stretto Platform™ server solutions, enable operators, OEMs and enterprises large and small around the globe to offer a seamless and unified over-the-top (OTT) communications experience across both fixed and mobile networks. The Bria and Stretto combination enables an improved user experience as an overlay to the most popular UC and IMS telephony and applications servers on the market today. Standards-based, cost-effective and reliable, CounterPath's award-winning solutions power the voice and video calling, messaging, and presence offerings of customers such as AT&T, Avaya, BroadSoft, BT, Cisco Systems, GENBAND, Metaswitch Networks, Mitel, NEC, Network Norway, Nokia, Rogers and Verizon. Visit www.counterpath.com. Bria X is a new service offering from CounterPath that provides SMBs and enterprises with an easy and efficient solution for adding secure team messaging, presence and screen sharing services on top of existing hosted or premise-based IP voice services. With apps available for desktop, smartphone and tablet devices, and up to three downloads per subscription, businesses can easily add mobile and BYOD options for their employees and provide them with the flexibility to be reached on the device of their choice in the method that makes the most sense. And with the Bria X Web Platform, IT administrators can set up, provision and manage accounts all from one central, web-based dashboard. For more information, visit www.bria-x.com.


N'EST PAS DESTINÉ À LA DISTRIBUTION AUX AGENCES DE PRESSE AMÉRICAINES NI À LA DIFFUSION AUX ÉTATS-UNIS Pediapharm inc. (la « Société ») (TSX CROISSANCE:PDP) est heureuse d'annoncer le dépôt de ses résultats financiers pour le troisième trimestre clos le 31 décembre 2016. Ils ont été établis conformément aux Normes internationales d'information financière (« IFRS ») et tous les montants sont en dollars canadiens, à moins d'indication contraire. FAITS SAILLANTS DE LA PÉRIODE CLOSE LE 31 DECEMBRE 2016 Pour le trimestre clos le 31 décembre 2016, les revenus totaux se chiffraient à 1 773 044 $ (1 022 539 $ pour le trimestre clos le 31 décembre 2015), ce qui constitue une augmentation de 73 %, notamment : Pour la période de neuf mois close le 31 décembre 2016, les revenus totaux se chiffraient à 4 548 351 $ (3 099 916 $ pour la période de neuf mois close le 31 décembre 2015), soit une augmentation de 47 %. Dans le cas de RelaxaMC, seulement les revenus générés depuis la transaction du 19 septembre, 2016 sont inclus. Grâce à l'ajout récent de RelaxaMC, la Société affiche des flux de trésorerie positifs sur une période consécutive de 12 mois relativement à ses activités d'exploitation. Cela ne tient pas compte des investissements (prélancement et post-lancement) consacrés aux lancements de produits à venir (RupallMC en janvier 2017 et OtixalMC plus tard en avril 2017). Le 12 décembre 2016, la Société a annoncé que Santé Canada avait approuvé la commercialisation des gouttes auriculaires OtixalMC (ciprofloxacine à 0,3 % et acétonide de fluocinolone à 0,025 %) pour le traitement de l'otite moyenne aiguë (OMA) chez les enfants de six mois et plus ayant un drain transtympanique. Les gouttes auriculaires OtixalMC sont les premières et les seules fabriquées à partir d'une combinaison d'antibiotique et de stéroïde offertes en doses unitaires stériles sans agent de conservation. De nombreuses activités ont déjà eu lieu en prévision du lancement commercial d'avril 2017, date à partir de laquelle le produit devrait être offert au Canada. Bien qu'il y ait des différences dans les éléments inclus dans le fonds de roulement net, tel que le niveau d'inventaire plus élevé dû à l'ajout de RelaxaMC, la Société avait un fonds de roulement net de plus de 5 000 000 $ au 31 décembre 2016, représentant une légère hausse par rapport au 31 mars, 2016. Le 25 janvier 2017, la Société a annoncé le lancement commercial de RupallMC (rupatadine) au Canada. Ce médicament novateur contre les allergies est désormais offert sur ordonnance aux patients atteints d'allergie ou d'urticaire. RupallMC est actuellement en distribution chez les grossistes et les pharmacies. L'équipe de vente à l'échelle nationale de la Société a reçu une formation sur ce nouveau médicament unique et en discute avec les professionnels de la santé. RupallMC (rupatadine), qui existe sous forme de comprimé de 10 mg et de solution orale de 1 mg/ml, est indiqué pour le soulagement des symptômes de la rhinite allergique saisonnière, de la rhinite allergique apériodique et de l'urticaire chronique spontanée chez les patients de deux ans ou plus. RupallMC est le premier médicament antihistaminique d'ordonnance lancé dans la dernière décennie qui est indiqué pour le traitement de ces trois maladies et qui comprend une formule pour les enfants de plus de deux ans. Ce médicament sera commercialisé dans le marché canadien des antihistaminiques, estimé à 130 000 000 $ (données d'IMS). De plus, il bénéficiera d'une période d'exclusivité commerciale de huit ans et demi, accordée par le Bureau des médicaments brevetés et de la liaison de Santé Canada en vertu de l'article C.08.004.1 du Règlement sur les aliments et drogues. En février 2017, la Société a ajouté deux produits à la gamme de RelaxaMC. La direction estime que cette bonification se traduira par une hausse des revenus et une amélioration des marges brutes à partir du deuxième semestre de l'exercice 2018. Depuis janvier 2017, les analystes de Mackie Research Capital Corporation assurent la couverture de Pediapharm. « Nous sommes très heureux de notre croissance de 73% des revenus en comparaison au même trimestre de l'an dernier », déclare Sylvain Chrétien, président et chef de la direction de Pediapharm. « Nous avons intégré avec succès l'ajout des produits Relaxa dans notre structure commerciale avec des revenus qui sont toujours en voie d'atteindre 3 000 000 $ annuellement. De plus, nous avons mis tout récemment sur le marché le produit Rupall, une innovation dans le traitement des allergies, et les premiers signes avant-coureurs sont des plus prometteurs. Par la suite, ce sera au tour d'Otixal d'être disponible sur le marché dès avril prochain. Nul doute que Pediapharm entre dans une ère très prometteuse avec des croissances substantielles pour les prochains trimestres et années à venir. » La priorité de la Société reste l'exécution de son plan commercial au moyen des produits existants, notamment NYDAMD, traitement révolutionnaire des poux de tête et de leurs œufs. NYDAMD, qui a dégagé des produits de plus de 3 200 000 $ pour l'exercice 2016, devrait atteindre des produits de 4 200 000 $ à 4 400 000 $ pour l'exercice 2017 et recèle un potentiel qui pourrait porter les produits des activités ordinaires à un sommet annuel se chiffrant entre 6 000 000 $ et 8 000 000 $ dans les deux prochaines années (données d'IMS et estimations de la direction). Seulement avec NYDAMD, la suspension de naproxen et RelaxaMC, la Société a bon espoir de générer plus de 8 500 000 $ de revenus pour l'exercice 2018 (clos le 31 mars 2018). Ces chiffres ne tiennent pas compte des recettes tirées des nouveaux produits. L'objectif de la direction pour les prochains trimestres est d'optimiser les investissements dans le lancement de RupallMC et d'OtixalMC tout en conservant un bilan solide. La rétroaction positive constante d'importants leaders d'opinion dans le domaine des allergies confirme les estimations de la direction selon lesquelles RupallMC pourrait atteindre un sommet de ventes annuelles de 8 000 000 $ à 10 000 000 $ d'ici cinq ou six ans. Pour OtixalMC, la Société estime que le médicament pourrait atteindre un sommet de ventes annuelles de 4 000 000 $ d'ici cinq ou six ans. Comme Pediapharm a déjà en place une solide infrastructure, la direction s'attend à une hausse modeste des frais de vente et d'administration, même en tenant compte de l'importante croissance des revenus attendue dans les prochaines années. Pediapharm détient un portefeuille de produits issus de contrats d'exclusivité qui, selon la direction, permettra à la Société de réaliser son objectif, soit de générer entre 25 000 000 $ et 30 000 000 $ de produits annuels d'ici les cinq ou six prochaines années. Ce sommet prévu des ventes est basé sur les données d'IMS et les estimations de la direction concernant la part de marché visée pour chaque produit. Le tableau ci-dessous montre les sommets prévus des ventes pour les principaux produits. Maintenant que Pediapharm s'est dotée d'un solide portefeuille de produits, montré ci-dessus, sa stratégie de développement fondamentale s'est récemment centrée sur l'acquisition de produits déjà mis en marché et sur la copromotion de produits déjà homologués au Canada. Pour la majorité des produits du portefeuille, les investissements relatifs à la réglementation sont déjà faits. Le principal objectif de cette stratégie est d'assurer la rentabilité rapidement, tout en poursuivant les processus réglementaires relatifs au CUVPOSAMC, dont le dossier a été présenté à Santé Canada en août 2016. Parallèlement, Pediapharm continuera d'évaluer des licences exclusives et des acquisitions de produits potentielles. En bref, la Société jouit d'une situation de trésorerie avantageuse qui lui permettra de mettre en application sa stratégie, qui comprend le lancement récent de RupallMC et le lancement à venir d'OtixalMC en avril 2017. En outre, la Société s'attend à maintenir l'excellente croissance des revenus tirés de la vente des autres produits portant la marque de Pediapharm, dont NYDAMD, la suspension de naproxen et RelaxaMC. En parallèle, la Société est en train d'évaluer des acquisitions potentielles de produits. Son principal objectif est d'accélérer sa stratégie de générer des flux de trésorerie positifs dans un court laps de temps. Pediapharm est une société en pleine croissance dans le secteur pharmaceutique des produits spécialisés à marge élevée, et lorsque des occasions d'alimenter cette croissance se présentent, elle peut augmenter son capital pour obtenir le financement et la flexibilité nécessaires. Analyse des résultats d'exploitation pour la période close le 31 décembre 2016 Pour le trimestre clos le 31 décembre 2016, les revenus totaux ont atteint 1 773 044 $, contre 1 022 539 $ pour le trimestre clos le 31 décembre 2015, soit une augmentation de 73 %. Il s'agissait du premier trimestre entier de revenus de RelaxaMC depuis la transaction du 19 septembre 2016. Ces revenus sont d'ailleurs en voie d'atteindre 3 000 000 $ annuellement. Pour leur part, les revenus tirés de NYDAMD ont augmenté de 12 % et, d'après les données d'IMS de décembre 2016 (MAT), la croissance de NYDA est de 35%. La direction maintient sa projection de 4 200 000 $ à 4 400 000 $ pour l'exercice clos le 31 mars 2017. Finalement, les revenus tirés de la suspension de naproxen de Pediapharm ont bondi de 92 %. Pour la période de neuf mois close le 31 décembre 2016, les revenus totaux ont atteint 4 548 351 $, contre 3 099 916 $ pour la période de neuf mois close le 31 décembre 2015, soit une augmentation de 47 %. Ces revenus sont d'ailleurs en voie d'atteindre 3 000 000 $ annuellement. Pour leur part, les revenus tirés de NYDAMD ont augmenté de 25 % et, d'après les données d'IMS de décembre 2016 (MAT), la croissance de NYDA est de 35%. La direction maintient sa projection de 4 200 000 $ à 4 400 000 $ pour l'exercice clos le 31 mars 2017. Finalement, les revenus tirés de la suspension de naproxen de Pediapharm ont bondi de 86 %. Pour comparer des périodes, outre la marge brute en dollars, il est aussi pertinent d'examiner la marge brute en tant que pourcentage des revenus. Comme il n'y a pas de coût des ventes relativement aux revenus tirés des commissions, les pourcentages de la marge brute ci-dessous sont calculés à partir du coût des ventes et des revenus tirés de la vente de produits uniquement. Pour le trimestre clos le 31 décembre 2016, la marge brute en dollars a atteint 891 893 $, soit une hausse de 29 % (689 358 $ pour le trimestre clos le 31 décembre 2015). La marge brute en tant que pourcentage des revenus était de 48 % (64 % pour le trimestre clos le 31 décembre 2015). Ce résultat est attribuable à la fois au fait que RelaxaMC présente une faible marge brute en raison de la nature même de sa catégorie de produit et aux dépenses engagées dans le cadre de la transition de RelaxaMC vers Pediapharm (par exemple liées aux tests de stabilité, à l'achat de composantes ou à l'installation des solutions d'entreposage). Dans les prochains trimestres, vu la croissance attendue des revenus tirés de NYDAMD, de RupallMC et d'OtixalMC, RelaxaMC représentera un moins grand pourcentage des revenus et, pour cette raison, la direction s'attends à ce que la marge brute totale en tant que pourcentage des revenus s'améliorera pour ultimement se fixer entre 60 % et 70 %. Pour le trimestre clos le 31 décembre 2016, les frais de ventes et d'administration s'élevaient à 1 656 245 $ (1 534 995 $ pour le trimestre clos le 31 décembre 2015). Bien que les charges réglementaires relatives aux dossiers de Santé Canada pour RupallMC et OtixalMC soient nettement inférieures à celles de l'exercice précédent, la Société a fait d'importants investissements en préparation du lancement commercial prochain de ces deux produits. Ces investissements comprennent la création d'un comité consultatif où siègent d'importants leaders d'opinion de partout au Canada, un colloque médical, de la formation approfondie et l'achat de données externes (IMS) pour mieux comprendre les dynamiques du marché et assurer le succès du lancement. Pour la période de neuf mois close le 31 décembre 2016, les frais de vente et d'administration ont diminué de 55 182 $ pour se fixer à 4 931 854 $ (4 987 036 $ pour la période de neuf mois close le 31 décembre 2015). Comme Pediapharm a déjà en place une solide infrastructure, la direction s'attend à une hausse modeste des frais de vente et d'administration, même en tenant compte de l'importante croissance des revenus attendue dans les prochaines années. Il n'y a eu aucun autre revenu pour le trimestre clos le 31 décembre 2016. Pour la période de neuf mois close le 31 décembre 2016, la Société a reçu le second et dernier versement de 2 000 000 $ US en espèces pour la vente des droits américains de la suspension de naproxen dans le cadre d'une transaction évaluée à environ 4 250 000 $ US. La perte d'exploitation pour le trimestre clos le 31 décembre 2016 s'est élevée à 783 507 $, contre une perte d'exploitation de 1 084 646 $ pour le trimestre clos le 31 décembre 2015. L'augmentation des revenus est la principale cause de cette amélioration de 301 139 $ par rapport au trimestre clos le 31 décembre 2015. Le bénéfice d'exploitation pour la période de neuf mois close le 31 décembre 2016 s'est élevé à 328 161 $, contre une perte d'exploitation de 3 234 294 $ pour la période de neuf mois close le 31 décembre 2015. L'augmentation des revenus et du bénéfice brut a contribué à l'amélioration de 992 255 $ par rapport à la période de neuf mois close le 31 décembre 2015. De plus, la Société a bénéficié de la vente susmentionnée de ses droits américains de la suspension de naproxen, qui a eu un effet positif de 2 570 200 $ pour la période de neuf mois close le 31 décembre 2016, ce qui élève l'amélioration totale du bénéfice d'exploitation à 3 562 455 $ par rapport à la période de neuf mois close le 31 décembre 2015. Pour le trimestre clos le 31 décembre 2016, le résultat net correspondait à une perte de 1 047 750 $, contre une perte nette de 1 288 020 $ pour le trimestre clos le 31 décembre 2015. Pour le trimestre clos le 31 décembre 2016, l'écart entre le résultat d'exploitation et le résultat net s'explique surtout par 272 919 $ de charges financières. La majorité de ces charges font suite au placement privé de débentures convertibles garanties et de bons de souscription de la Société du 31 mars 2015. Ce placement a généré un produit brut total de 5 500 000 $. Pour la période de neuf mois close le 31 décembre 2016, le résultat net correspondait à une perte de 443 274 $, contre une perte nette de 3 836 677 $ pour la période de neuf mois close le 31 décembre 2015. Pour la période de neuf mois close le 31 décembre 2016, l'écart entre le résultat d'exploitation et le résultat net s'explique surtout par 804 905 $ de charges financières. La majorité de ces charges font suite au placement privé de débentures convertibles garanties et de bons de souscription de la Société du 31 mars 2015. Ce placement a généré un produit brut total de 5 500 000 $. Pediapharm est la seule entreprise pharmaceutique canadienne spécialisée en pédiatrie. Elle a pour mission de commercialiser des produits pédiatriques novateurs visant à améliorer la santé et le bien-être des enfants au Canada. Depuis sa création en 2008, Pediapharm a conclu de nombreux accords commerciaux avec des partenaires du Canada et d'autres pays. Son portfolio de produits innovateurs compte notamment NYDAß┤╣ß┤░, un traitement révolutionnaire des poux de tête; EpiCeramß┤╣ß┤░, une crème non stéroïdienne pour le traitement de l'eczéma; la suspension de naproxen, utilisée dans le traitement de la douleur et de l'inflammation causées par diverses affections, dont l'arthrite juvénile; RupallMC, une innovation dans le traitement médical des allergies avec un mode d'action unique; les gouttes auriculaires OtixalMC, qui sont les premières et les seules fabriquées à partir d'une combinaison d'antibiotique et de stéroïde offertes en doses unitaires stériles sans agent de conservation; ainsi que CuvposaMC, pour la sialorrhée grave, qui est présentement sous réserve de l'approbation de Santé Canada. Le présent communiqué de presse contient des énoncés prospectifs et d'autres énoncés qui ne sont pas des faits historiques. Ces énoncés prospectifs sont assujettis à des risques connus ou inconnus, à des incertitudes et à des hypothèses qui pourraient donner lieu à des résultats très différents des résultats visés et des résultats ou événements prévus dans ces énoncés prospectifs. Par conséquent, les investisseurs sont avisés qu'ils ne doivent pas se fier indûment à ces énoncés prospectifs. Les énoncés prospectifs figurant dans le présent communiqué de presse sont formulés à la date de publication. À moins d'y être tenue selon les lois applicables, la Société nie expressément toute intention ou obligation de mettre à jour ou de réviser tout énoncé prospectif, que ce soit à la lumière de nouveaux renseignements, d'événements futurs ou autrement. L'information prospective reflète les attentes ou croyances actuelles de la Société selon les renseignements qu'elle détient à ce jour, et ces renseignements sont fondés sur différentes hypothèses et assujettis à des risques et incertitudes décrits plus amplement aux pages 35 à 41 de la circulaire d'information de la direction de Chelsea Acquisition Corporation du 12 novembre 2013 qui peut être consultée sur SEDAR, à l'adresse www.sedar.com, ainsi qu'aux autres risques découlant du fait qu'elle est une entreprise pharmaceutique spécialisée. La Bourse de croissance TSX. et son fournisseur de services de réglementation (au sens attribué à ce terme dans les politiques de la Bourse de croissance TSX) ne peuvent être tenus responsables de l'exactitude ou de la véracité du présent document.


BARCELONA, SPAIN--(Marketwired - March 01, 2017) - MOBILE WORLD CONGRESS -- This week at Mobile World Congress 2017, VMware Inc. ( : VMW) is demonstrating the company's leadership driving the digital transformation of telecom, cable and mobile operators into agile service providers. Through VMware's unified software-defined architecture spanning Network Functions Virtualization (NFV), Mobility and the Internet of Things (IoT), global communications service providers (CSPs) can benefit from potential new revenue streams with sustainable cost reductions, increased flexibility and security and a modernized network that is 5G and Internet of Things (IoT) ready. VMware's complete portfolio of solutions for CSPs is on display this week in Hall 3 Stand 3K10. Today, CSPs must balance high customer expectations with business challenges such as increased competition and cost, lack of service differentiation, and new business models. They must simultaneously look internally at how they build their networks for both today and tomorrow, while looking externally for new service opportunities. Over-the-Top (OTT) providers have the benefit of speed and agility to deliver new high margin services without having the constraints of network build-out costs, eroding revenue and creating customer churn. On the horizon, 5G networks represent the next major wave of mobile infrastructure upgrades. Accelerating capacity demands from high-bandwidth services such as video and virtual reality, coupled with the distributed nature of infrastructure components in IoT, could significantly impact the reliability, performance and quality of experience delivered to subscribers if networks are not architected correctly. For CSPs' business customers, mobile computing presents new management and security challenges, creating an opportunity for new managed services offerings. VMware is a proven, strategic software innovator that is helping CSPs successfully deliver new services faster and improve overall customer satisfaction, while driving down costs. With VMware Cross-Cloud Architecture™ combined with virtual network functions (VNFs) and applications from a rich ecosystem of partners, global CSPs are delivering services such as VoLTE, IMS, enterprise SD-WAN, mobility and workspace management, as well as IoT services for connected cars, smart stadiums and cities. VMware's ETSI-compliant NFV platform enables network modernization so CSPs can deliver differentiated services today, with 5G readiness for the future. CSPs partner with VMware to deliver Enterprise Mobility Management and Digital Workspace services to customers across multiple mobile and desktop platforms. On the IoT front, VMware helps CSPs maximize the opportunity by streamlining how they deploy, manage, monitor, and secure IoT infrastructure. "In the fast-evolving technology landscape, continued success and growth for Telcos and CSPs depends on transforming from connectivity providers to innovators in delivering rich services, content and personalized experiences," said Shekar Ayyar, executive vice president and General Manager, Telco Group at VMware. "Software-defined, virtualized architectures are the catalysts helping service providers modernize their networks, making them 5G ready, and opening their businesses to new possibilities. With VMware's software-defined architecture for NFV, Mobility, and IoT, CSPs can accelerate service innovation, improve operations and management, and deliver a range of scalable and secure mobile applications and services." Foundation for Network Transformation and Modernization -- VMware vCloud NFV With more than 80 NFV deployments by more than 45 CSPs serving more than 300 million subscribers worldwide, VMware vCloud® NFV™ accelerates service innovation and delivery, reduces costs, and simplifies network operations. The vCloud NFV platform enables organizations to deploy a multi-vendor and multi-function NFV platform today that delivers service automation, secure multi-tenancy, operations management and carrier grade reliability with 5G readiness. To date,34 VNFs have been certified as VMware Ready for NFV, with many being deployed in production customer environments today. By deploying vCloud NFV platform, CSPs can build, provision and sell new services in days instead of months, positively influence customer quality of experience, and significantly improve OPEX and CAPEX. Open standards and open source will play a major role in defining the future architectures upon which CSPs deliver services. With VMware Integrated OpenStack, the vCloud NFV platform supports an open architecture for integration and interoperability. Additionally, VMware is a leader of many leading open source initiatives. VMware recently joined AT&T, China Mobile and the world's leading operators as a founding member of the Open Network Automation Platform (ONAP) Project. ONAP comes from the merger of open source ECOMP and Open Orchestrator Project (OPEN-O), two of the largest open source networking initiatives, to create a harmonized and comprehensive framework for real-time, policy-driven software automation of virtual network functions that will enable software, network, IT and cloud providers and developers to rapidly create new services. VMware is also a major participant in OpenStack, Open vSwitch and Open Source MANO (OSM). Read the press release about the launch of VMware vCloud NFV 2.0 Driving Revenue through Enterprise Mobility Management and Digital Workspace Services VMware enables CSPs to offer a range of enterprise mobility services for customers at all stages of the mobility lifecycle. Carriers resell VMware AirWatch®, the leader in Enterprise Mobility Management, and offer AirWatch as a managed services solution through the VMware vCloud Air™ Network Program. AirWatch enables management and security of a broad array of customer devices, including BYO devices and those sold by the CSP, and enables enterprise collaboration services such as email and file sharing that drive data plan usage. CSPs are increasingly adding Digital Workspace services through VMware Workspace™ ONE™, which optimizes mobile user productivity and convenience by enabling an "any app, any device" experience. By offering all applications -- mobile, web, Windows (including Windows 10), virtual, or cloud -- through a single app portal with identity integration for single sign-on, carriers can further maximize revenue from enterprise data usage, software resale and services opportunities. VMware helps CSPs develop a portfolio of professional services that include consultative/strategic, deployment, support, and managed services offerings. Read this news about the launch of new AirWatch Managed Services Cost-Effective, Scalable IoT from the Edge to the Cloud VMware helps CSPs maximize the opportunity for IoT internally, and with customers, by streamlining how they deploy, manage, monitor, and secure IoT infrastructure. VMware supports customers across the entire IoT value chain -- things, edge, data, network, applications, and users -- with secure, enterprise-grade, end-to-end operations management and infrastructure solutions for IoT. With VMware, customers can manage across millions of things easily, operate smarter with an accurate health of all things and innovate faster by speeding up delivery of IoT use cases. Read this news about VMware and HARMAN's partnership in IoT Analyst, Partner and Customer Commentary "VMWare is addressing the need of CSPs to serve more use cases for more customer types, all while integrating and unifying the underlying network and datacenter infrastructure. At the very least, this transformed infrastructure has to accommodate cloudification and simplified management. Due to the increasing demand for customized, targeted services, CSPs need to be able to bring those services to market quickly, manage them more efficiently, and provide them across a growing number of devices and networks." - Andy Hicks, Research Director, IDC EMEA Telecommunications Group "IIJ has deployed VMware virtualized infrastructure and management in production across our network services, cloud service and IT environments. Collaborating with VMware, we delivered the IIJ Omnibus Service to transform the economics our CPE-based services. VMware Cross-Cloud Architecture enables us to implement a unified, multi-service platform that simplifies ongoing operations management and delivers the agility to adapt quickly to new service opportunities." - Shinri Kimura, General Manager, Service Infrastructure Division, Internet Initiative Japan Inc. "The corporate market is a growth segment for M1, and we have continually enhanced our offerings to better serve these customers through our connectivity solutions and cloud-based data center. Our next-generation platform powered by VMware NSX®, enables us to create a complete network and security virtualization platform, with advanced security capabilities that enable enterprises seeking scalability and better performance." - Mr. Willis Sim, Chief Corporate Sales and Solutions Officer, M1 Limited "As Singapore's first fully integrated info-communications company, StarHub is focused on empowering its customers with world-class information, communication and entertainment services. Virtualizing our critical applications with VMware has enabled StarHub to deliver a more agile and flexible infrastructure that responds faster to dynamic business demands. Hardware resources are better optimized, achieving significant savings without compromising application performance. Applications can be easily moved across servers, providing higher availability and scalability resulting in a seamless and better customer experience." - John Tan, Chief Information Officer, StarHub "As communications service providers undertake massive digital transformation initiatives, they are increasingly investing in modern network architectures, applications and connectivity. We see this as a huge opportunity to offer CSPs a unique combination of scalable solutions to meet their needs. As the de facto industry standard in virtualization, VMware will continue to be strategic in helping to grow our partners' capabilities and portfolio of offerings." - Jay Snyder, Senior Vice President, Global Alliances, Service Providers and Industries, Dell EMC. "Atos and VMware are collaborating to drive network modernization through NFV adoption, which will result in reduced costs and improved agility for CSPs. Together with other industry leaders, we are building a global multi-vendor NFV Laboratory in Grenoble, France focused on testing, validating and demonstrating mission critical NFV services and simulate real-world NFV scenarios. The NFV Laboratory will work with multiple VNF providers to understand and optimize network and business performance based on known and measured performance." - Paul Davey, CTO, Atos About VMware VMware, a global leader in cloud infrastructure and business mobility, helps customers accelerate their digital transformation. VMware enables enterprises to master a software-defined approach to business and IT with VMware Cross-Cloud Architecture™ and solutions for the data center, mobility, and security. With 2016 revenue of $7.09 billion, VMware is headquartered in Palo Alto, CA and has over 500,000 customers and 75,000 partners worldwide. VMware, Cross-Cloud Architecture, vCloud, vCloud NFV, VMware Ready, AirWatch, vCloud Air, vCloud Air Network, VMware Workspace, and Workspace ONE are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions. All other marks and names mentioned herein may be trademarks of their respective companies.


News Article | February 22, 2017
Site: www.prnewswire.co.uk

Together with BICS, PGi's Mobile Collaboration Exchange Offers HD Audio Conferencing on Any Mobile Device, from Anywhere in the World ATLANTA, Feb. 22, 2017 /PRNewswire/ -- Today PGi, the world's largest dedicated provider of collaboration software and services, and BICS, a leading international communications enabler, announced that they have conducted their first Voice over LTE (VoLTE) High Definition (HD) audio conference call. The VoLTE conference call was powered by PGi's mobile collaboration exchange which connects an operator's IMS based VoLTE service to PGi's cloud-enabled IP conferencing infrastructure and enables mobile operators to host crystal-clear, HD conference calls. BICS' IPX VoLTE Hub has been instrumental in bridging the HD VoLTE calls originating from the mobile operator's network to PGi's mobile collaboration exchange. With more than one in three operators investing in LTE-advanced system deployments and one in three conference call attendees using a mobile phone, the mobile collaboration exchange allows mobile operators to seamlessly deliver low-bandwidth, high-quality audio conference calls over an LTE network. BICS' IPX VoLTE Hub is enabling international VoLTE calls providing enhanced quality of experience to end-users and assisting mobile operators to realize the All IP migration. IPX VoLTE Hub is empowered with the best in class protocol normalisation and media transcoding capabilities, which are vital in maintaining the E2E HD sound quality of VoLTE voice calls. Jorn Vercamert, VP Communication Solutions at BICS commented: "More and more enterprises are moving their communication services to the cloud. BICS has visualized the importance of mobility and cloud virtual numbers so as to equip workers with the tools that provide flexibility and collaboration on the go. This is particularly important for knowledge workers that travel frequently or work remotely, rather than being chained to their desks. By partnering with PGi, BICS has facilitated a higher-quality, faster and more reliable calling experience, which is crucial in today's competitive and fast-moving business landscape. Businesses can build value-added services and improve customer satisfaction, trusting the connectivity and interoperability services provided by international communication providers like BICS." Pat Harper, CTO of PGi stated, "PGi is proud of its legacy as a cloud innovator and is thrilled to work with carriers to continue to grow our offerings with our mobile collaboration exchange. While we know and understand that business is conducted on a global scale, we also know that mobile networks are not always compatible globally. Together with BICS, our mobile-first, cloud collaboration approach is standardizing the way that mobile operators can connect to PGi's audio conferencing capabilities and offer a better experience for their enterprise and end-users alike. PGi is utilizing BICS' secure global network infrastructure and its advanced capabilities to offer a superior audio conferencing experience." Divya Ghai Wakankar, Head of Innovation and VoLTE Product Management at BICS stated, "At BICS, we have a track record of innovative solutions that enhance the end-user experience. With the BICS IPX VoLTE solution and our Cloud numbers offering we are excited to provide best-in-class support to the business voice customers. Together, BICS and PGi have spawned a new beginning of HD business voice experience for the global workforce." All trademarks referred to in this release are the property of their respective owners. About Premiere Global Services, Inc. │ PGi PGi is the world's largest dedicated provider of collaboration software and services. For more than 25 years, our broad portfolio of products has served the end-to-end collaboration needs of enterprises. Accessible anywhere, anytime and on any device, PGi's award-winning collaboration solutions drive productivity and teamwork for approximately 50,000 customers around the world. To learn more, visit us at pgi.com. About BICS BICS is recognized in the wholesale communications market as a top global voice carrier and the leading provider of mobile data services. We aim at bridging the telecom world with the new unconventional communication providers worldwide. Our innovative suite of solutions for Voice, Messaging, Data & Connectivity, Business Intelligence & Analytics, Fraud & Security, Roaming, Global IoT and Asset Monetization are designed to bring value to our customers' businesses. BICS is headquartered in Brussels with regional offices in Bern, Dubai, Madrid, New York, San Francisco and Singapore. We also have a satellite office in Beijing and local representation in Accra, Cape Town, Miami, Montevideo, Quito, Nairobi and Toronto.


News Article | February 24, 2017
Site: www.businesswire.com

DANBURY, Connecticut, e RESEARCH TRIANGLE PARK, Carolina del Nord--(BUSINESS WIRE)--Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE: Q) ha annunciato oggi il prezzo per l'offerta di 1,425 miliardi di euro in ricavi lordi derivati da titoli privilegiati emessi dalla sua consociata interamente controllata Quintiles IMS Incorporated (“Emittente”). L'offerta è stata incrementata rispetto al montante figurativo aggregato di 850 milioni di euro annunciato precedentemente. In conseguenza di tale incremento, sebbene l'Emittente intenda tuttora rifinanziare tutti i prestiti a scadenza B in essere nell'ambito della sua linea creditizia privilegiata garantita con un prestito a scadenza B esteso e con prezzo modificato come annunciato in precedenza, essa ha deciso di non incrementare il prestito a scadenza B.


News Article | February 24, 2017
Site: www.businesswire.com

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles IMS Holdings, Inc. heeft vandaag de prijs bekendgemaakt van zijn uitgifte van preferente obligaties ter waarde van 1,425 miljard euro, die worden verkocht door zijn dochteronderneming Quintiles IMS Incorporated. Dit is een opschaling van de eerder aangekondigde obligatie-uitgifte met een totale waarde van 850 miljoen euro. Als gevolg van deze uitbreiding kiest Quintiles ervoor niet langer zijn term-B-kredietfaciliteit te verruimen. Het bedrijf is nog wel voornemens alle uitstaande term-B-leningen van zijn preferente en gedekte kredietfaciliteit te herfinancieren met een verlengde en opnieuw geprijsde term-B-faciliteit, zoals eerder is aangekondigd. De netto-opbrengst van de obligatie-uitgifte en de herfinanciering worden gebruikt voor de financiering van bestaande schulden, betaling van kosten die verbonden zijn met de obligatie-uitgifte en andere bedrijfsactiviteiten, die mogelijk bestaan uit het terugkopen van aandelen van dochterondernemingen en belangrijke aandeelhouders en overnames. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, welke als enige rechtsgeldig is.


DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE: Q) today announced that its wholly owned subsidiary, Quintiles IMS Incorporated (the “Issuer”), intends to raise €850 million in gross proceeds through an offering of senior notes due 2025. In connection with the notes offering, the Issuer intends to refinance all of the outstanding term B loans under its senior secured credit facility with an extended, upsized and repriced term B loan facility in an aggregate principal amount equal to $3,065 million equivalent amount comprised of both U.S. dollar denominated term B loans and euro denominated term B loans. The extended term B loans will mature in 2024 and will represent an increase of approximately $600 million from the amount of term B loans currently outstanding. The net proceeds from the notes offering and the refinancing will be used to refinance certain indebtedness of the Issuer, to pay fees and expenses related to the notes offering and the refinancing and for other general corporate purposes, which may include share repurchases, including the repurchase of shares from affiliates and significant shareholders, and future acquisitions. The consummation of the notes offering and the refinancing are each subject to market and other conditions. Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors including the failure to consummate the notes offering and the refinancing and potential changes in market conditions that could cause actual results to differ materially. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes. The notes to be offered have not been, and will not be, registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933. The notes are being offered only to qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act of 1933 and outside the United States only to non-U.S. investors pursuant to Regulation S. QuintilesIMS (NYSE: Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles Transnational and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial, bringing customers a unique opportunity to realize the full potential of innovations and advanced healthcare outcomes. As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, and to identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. Click here to subscribe to Mobile Alerts for QuintilesIMS.


News Article | February 27, 2017
Site: www.prnewswire.co.uk

Summit Tech ha lanzado la realidad virtual RCS en tiempo real y realidad aumentada llamada - VRcalling.com. La solución permite a los operadores inalámbricos añadir soporte para servicios RCS como IR.92/94 desde entornos VR/AR. Mientras que muchas experiencias de RV aislan a los usuarios de la vida real, Summit comienza conectando personas reales mediante secuencias de vídeo 360º en tiempo real incluyendo soporte para entornos virtuales. Los usuarios se conectan a través de servicios de comunicación estandarizados a nivel mundial como RCS y VoLTE asegurando accesibilidad masiva permitiendo a los usuarios de RV compartir su experiencia con, bueno, prácticamente cualquier persona con un smartphone. Los usuarios de Oculus Rift, HTC Vive o Gear VR se conectan en vivo a secuencias de RV, entonces simplemente VRcalling a sus amigos en dispositivos RCS o ViLTE permitidos, los usuarios comparten sus experiencias en tiempo real - sin aplicación necesaria. Además, mientras están conectados a secuencias, los usuarios pueden publicar su presencia social que permite la comunicación entre cualquier usuario conectado a la corriente. VRcalling permite nuevas experiencias de alto valor tales como: - Entretenimiento inmersivo de la transmisión en vivo - conectando a secuencias 360° desde eventos deportivos o conciertos musicales, los operadores pueden poner sus abonados en el centro de la acción, lo que les permite mirar alrededor y experimentar la situación como un asistente físico compartiendo la secuencia con amigos a través de RCS. - Reuniones/formación inmersivos - dando contexto visual y vistas de 360° de los asistentes y ubicación, reuniones de negocios inmersivas divididas entre sesiones de telepresencia plana y asistencia física. - Entretenimiento inmersivo - los estudiantes pueden explorar lugares educativos como museos, galerías y observatorios e interactuar con alumnos en lugares distantes a través de videollamadas superpuestas y chat grupal. RCS es la plataforma de comunicación y conversación de próxima generación desplegada por los operadores con servicios que van desde llamada enriquecida a chatbots. No limitado a RCS smartphones, los usuarios acceden a VRcalling a través de auriculares VR o gafas AR para experiencias inmersivas, o tabletas y navegadores web como alternativas fácilmente accesibles. Alido Di Giovanni, director general de Summit comentó: "Queremos capacitar a los operadores para lanzar servicios VR/AR rápidamente y asegurar nuevas fuentes de ingresos. Para facilitar a la operadores pilotar RCS VR, también estamos demostrando un servicio de nube IMS de marca blanca. Summit Tech también mostrará el innovador coche conectado basados en IMS y servicios gestionados por el operador apoyando Cat M1 y NB-IoT.


News Article | March 1, 2017
Site: globenewswire.com

BARCELONA, Spain, March 01, 2017 (GLOBE NEWSWIRE) -- Qorvo® (Nasdaq:QRVO), a leading provider of innovative RF solutions that connect the world, today announced two highly-integrated dual channel switch-LNA modules for base station implementations of massive multiple-input/multiple-output (MIMO). When combined with Qorvo’s GaN-based integrated driver and power amplifier module, the dual channel switch-LNA modules provide a complete, highly integrated solution for wireless infrastructure manufacturers seeking to quickly and cost-effectively implement pre-5G massive MIMO networks. Mobile operators are increasing data capacity with the deployment of sub-6 GHz massive MIMO networks. Strategy Analytics predicts that 5G networks using massive MIMO will be operational by 2020 and that there will be approximately 700 million 5G connections by 2025. Massive MIMO allows base stations to transmit multiple streams of data, while beamforming will bring higher gain and power, allowing for greater data capacity. James Klein, President of Infrastructure and Defense at Qorvo, said, “Qorvo is uniquely positioned to deliver complete system solutions that leverage our broad portfolio of highly differentiated products and internally developed technologies. With today’s product announcement, we expand our portfolio of receive and transmit front-end modules for additional frequency bands targeted at pre-5G and 5G wireless infrastructure, in anticipation of more spectrum being made available below 6 GHz.” Qorvo's QPB9318 and QPB9319 are highly integrated dual channel switch-LNA modules that support frequency bands below 5GHz. The dual channel switch-LNA modules pair with Qorvo’s high performance GaN-based QPA2705 to provide a complete massive MIMO RF solution. At IMS 2016, Qorvo demonstrated industry-leading ultra-wideband linearization results with the QPA2705. With Qorvo’s complete solution, operators are able to implement highly efficient, small form-factor massive MIMO transceivers for next-generation base stations. The QPB9318 and QPA2705 are currently shipping in production volumes to large base station OEMs, and samples of the QPB9319 will be available in the June quarter. Qorvo is paving a path to 5G by helping define 5G standards as a delegate to 3GPP and through close collaboration with the leading wireless infrastructure manufacturers, network operators, chipset providers and smartphone manufacturers. Qorvo has helped conduct dozens of 5G field trials and is uniquely positioned to accelerate the transition to 5G with a broad portfolio of innovative RF products covering frequencies ranging from 600 MHz to 80 GHz Qorvo is solving RF complexity and showcasing the industry’s most comprehensive portfolio of advanced RF solutions at Mobile World Congress (MWC 2017), from February 27 through March 2 in Hall 2, Stand 2i25. About Qorvo Qorvo (NASDAQ:QRVO) makes a better world possible by providing innovative RF solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers' most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks and defense radar and communications.  We also leverage our unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things, and other emerging applications that expand the global framework interconnecting people, places and things. Visit www.qorvo.com to learn how Qorvo connects the world. Qorvo is a registered trademark of Qorvo, Inc. in the U.S. and in other countries. This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently.  You should be aware that the forward-looking statements included herein represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those expressed or implied by forward-looking statements.  We do not intend to update any of these forward-looking statements or publicly announce the results of any revisions to these forward-looking statements, other than as is required under the federal securities laws.  Qorvo's business is subject to numerous risks and uncertainties, including variability in operating results, the inability of certain of our customers or suppliers to access their traditional sources of credit, our industry's rapidly changing technology, our dependence on a few large customers for a substantial portion of our revenue, a loss of revenue if contracts with the U.S. government or defense and aerospace contractors are canceled or delayed, our ability to implement innovative technologies, our ability to bring new products to market and achieve design wins, the efficient and successful operation of our wafer fabrication facilities, assembly facilities and test and tape and reel facilities, our ability to adjust production capacity in a timely fashion in response to changes in demand for our products, variability in manufacturing yields, industry overcapacity and current macroeconomic conditions, inaccurate product forecasts and corresponding inventory and manufacturing costs, dependence on third parties and our ability to manage platform providers and customer relationships, our dependence on international sales and operations, our ability to attract and retain skilled personnel and develop leaders, the possibility that future acquisitions may dilute our shareholders' ownership and cause us to incur debt and assume contingent liabilities, fluctuations in the price of our common stock, additional claims of infringement on our intellectual property portfolio, lawsuits and claims relating to our products, security breaches and other similar disruptions compromising our information and exposing us to liability, and the impact of stringent environmental regulations. These and other risks and uncertainties, which are described in more detail in Qorvo's most recent Annual Report on Form 10-K and in other reports and statements filed with the Securities and Exchange Commission, could cause actual results and developments to be materially different from those expressed or implied by any of these forward-looking statements.

Loading IMS collaborators
Loading IMS collaborators